MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

Acute lymphoblastic leukemia (ALL) in infants is an aggressive malignancy with a poor clinical outcome, and is characterized by translocations of the Mixed Lineage Leukemia (MLL) gene. Previously, we identified RAS mutations in 14-24% of infant ALL patients, and showed that the presence of a RAS mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerstjens, Mark, Driessen, Emma M.C., Willekes, Merel, Pinhanços, Sandra S., Schneider, Pauline, Pieters, Rob, Stam, Ronald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362448/
https://www.ncbi.nlm.nih.gov/pubmed/27588400
http://dx.doi.org/10.18632/oncotarget.11730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362448/
https://www.ncbi.nlm.nih.gov/pubmed/27588400
http://dx.doi.org/10.18632/oncotarget.11730

Ejemplares similares